Cash and Cash Equivalents - As of December 31, 2025, the company had cash and cash equivalents totaling $12,040,789, primarily invested in demand deposit accounts and money market funds[474]. - The company considers all highly liquid debt instruments purchased with a maturity of three months or less as cash equivalents, focusing on capital preservation and liquidity needs[474]. Market Risk and Investment Income - The company's cash equivalents are subject to market risk due to changes in interest rates, which may adversely affect the market value of fixed-rate securities[475]. - Future investment income may fall short of expectations due to changes in interest rates, potentially leading to losses in principal if securities are sold at a loss[475].

Financial Performance - Future Fintech reported a fiscal year-end revenue of $50 million, representing a 20% increase compared to the previous year[11] - The company reported a net loss of $2 million for the fiscal year, primarily due to increased operational costs[11] Business Strategy - The company aims to expand its supply chain financing services in China, targeting a market growth rate of 15% annually[13] - Future Fintech plans to introduce three new financial technology products in the next fiscal year, with an estimated investment of $5 million[11] - Future Fintech is exploring potential mergers and acquisitions to strengthen its market position in the financial technology sector[11] - The company anticipates a 10% increase in customer acquisition through enhanced digital marketing strategies[11] Regulatory and Compliance Risks - Future Fintech is subject to regulatory risks in China, which could affect its ability to operate and expand[21] - Compliance with the New Overseas Listing Rules is currently lacking, which may lead to sanctions from the CSRC[21] - The Holding Foreign Companies Accountable Act poses regulatory risks that could affect Future FinTech's operations in mainland China[21] - The Chinese government's influence over business operations may result in material changes that could hinder Future FinTech's ability to offer securities[21] - Uncertainties in the interpretation of PRC laws may negatively impact Future FinTech's business operations and share value[21] Legal and Litigation Issues - The company is currently involved in litigation with FT Global Capital, which may impact its financial condition[13] - Future FinTech is involved in disputes and legal proceedings that could materially affect its business and financial condition[18] Market and Competitive Landscape - The supply chain financing service industry in China is rapidly evolving and increasingly competitive, posing risks to Future FinTech's market position[18] Cybersecurity Measures - The company has implemented cybersecurity measures to mitigate risks, with an estimated cost of $1 million for the upcoming year[18] - Cybersecurity risks may lead to increasing costs for Future FinTech as it seeks to minimize these risks[18] Stock Market Compliance - Future Fintech's common stock has faced delisting risks from NASDAQ due to compliance issues, necessitating a reverse stock split[21] - Future FinTech has implemented a reverse stock split to address NASDAQ minimum bid price requirements, with no assurance of future compliance[21] - Future FinTech's common stock has faced delisting risks from NASDAQ in recent years[21] - Future FinTech's listing readiness and preparatory consulting services are in an early stage, subject to regulatory interpretation and execution risks[18]

Financial Performance and Losses - The company incurred net losses of approximately $34.0 million and $35.5 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of approximately $407.1 million as of December 31, 2025[87][88]. - The company expects to continue incurring significant losses for at least the next few years due to ongoing expenses related to product development and market entry[87]. - The company anticipates substantial pricing pressure from automotive OEMs, Tier 1 suppliers, and lidar competitors, which may adversely affect revenue from product licensing and sales[122]. - The company is facing significant challenges in achieving profitability due to high costs associated with strategic initiatives and the early stage of market opportunities, which may take years to generate demand[104]. - The company’s financial results are subject to significant quarterly fluctuations, influenced by factors such as order timing, pricing strategies, and customer purchasing cycles[95][96]. Capital and Funding - The company may need to raise additional capital to execute its business plan, which could lead to significant dilution for existing shareholders if capital is raised through equity issuance[90]. - The company has approximately $362.2 million of U.S. federal net operating loss carryforwards and approximately $268.7 million of state net operating loss carryforwards available to reduce future taxable income[187]. - Approximately $349.9 million of the U.S. federal operating loss carryforwards will be carried forward indefinitely, while approximately $12.2 million will begin to expire in 2033[187]. Market and Competitive Landscape - The company operates in a rapidly evolving market, making it difficult to predict future revenue and expenses accurately due to its limited operating history[100][101]. - The company is focused on developing strategic partnerships to enhance its market position and customer base[104]. - The company is pursuing opportunities in rapidly evolving markets, including autonomous driving and lidar-based ADAS applications, but faces uncertainty in customer adoption rates and demand for its products[159]. - The company operates in a highly competitive market with significant competition from companies with greater resources, which may lead to pricing pressure and reduced margins[170]. - Developments in alternative technologies, such as cameras and radar, may adversely affect demand for the company's lidar solutions, impacting financial results[176]. Supply Chain and Operational Risks - The company faces risks related to supply chain disruptions, including reliance on limited or single-source suppliers for key components, which could adversely affect product delivery and financial performance[85]. - A significant portion of components used in products are manufactured abroad, exposing the company to international risks such as tariffs and supply chain disruptions[114]. - The company has faced challenges in managing inventory and production, which could impact its ability to meet customer demand[104]. - The complexity of the company's products may lead to unforeseen delays or expenses due to defects or reliability issues, potentially harming market adoption and reputation[86]. - The company faces challenges in securing supply agreements due to potential renegotiations or terminations, which could adversely affect product pricing and future profitability[158]. Legal and Regulatory Risks - The company may face significant legal claims for product liability, which could result in direct or indirect costs adversely affecting business and operating results[150]. - The company is subject to various operational, financial, and regulatory risks associated with international markets[145]. - The company faces potential legal and regulatory proceedings that could impact profitability and financial position, including a claim for approximately $3.3 million from a former vendor[207]. - The company is subject to stringent compliance and reporting requirements related to product safety, which could impose significant civil penalties for violations[216]. - The company is subject to evolving regulatory schemes for autonomous driving and ADAS applications, which could impose limitations on lidar use and affect business operations[219]. Cybersecurity and Operational Disruptions - The company is subject to cybersecurity risks that could disrupt operations and compromise confidential information, with potential impacts on financial condition[195]. - A significant cyber incident could materially affect the company's business, prospects, financial condition, and operating results, with insurance coverage potentially insufficient to cover all losses[199]. - The company has implemented processes to mitigate cybersecurity risks, but these measures do not guarantee protection against potential cyber incidents[200]. Human Resources and Management - The company is highly dependent on its executive officers, and the loss of key personnel could adversely affect its business and operations[190]. - The company has faced challenges in attracting and retaining highly skilled personnel due to competition and stock price declines, impacting its ability to meet future needs[191]. - The company has not received an equity grant for over two years, increasing the risk of retention for its executive officers[191]. Stockholder and Market Risks - The company may experience significant volatility in its stock price due to retail investor interest, which could be unrelated to its operating performance[246]. - The company’s stock price could decline if analysts cease coverage or change their recommendations adversely[252]. - The exclusive forum provision in the company's Charter may limit stockholders' ability to bring claims in more favorable judicial forums, potentially discouraging lawsuits[260]. - The company does not expect to declare any dividends in the foreseeable future, which may require stockholders to rely on share sales for potential gains[261]. Environmental and Compliance Risks - The company is subject to environmental laws that could impose significant costs and delays in building production facilities, affecting financial condition[227]. - Compliance with the Dodd-Frank Act regarding conflict minerals may increase costs and limit the supply of certain metals used in manufacturing[229]. - The evolving regulatory landscape may necessitate costly updates to compliance measures, affecting operational costs and revenue[225].

Revenue Performance - Total revenue for Q4 2025 was $1,572 million, a 1% increase year-over-year, and full-year revenue reached $4,379 million, up 16% from 2024[4] - Rental Segment revenue grew 35% to $772 million in Q4 and 34% to $2,724 million for the full year, driven by significant customer demand[5] - Total revenues for the three months ended December 31, 2025, were $1,572 million, a slight increase from $1,553 million in the same period of 2024, while total revenues for the year ended December 31, 2025, reached $4,379 million, up from $3,764 million in 2024, representing a year-over-year growth of 16.3%[18] Profitability - Net income for Q4 2025 was $65 million, a 30% increase, while full-year net income was $40 million, up 1,233% from the previous year[5] - Gross profit for the three months ended December 31, 2025, was $441 million, compared to $341 million for the same period in 2024, indicating a gross profit margin increase from 22% to 28%[18] - Net income for the three months ended December 31, 2025, was $65 million, up from $50 million in the same period of 2024, while net income attributable to stockholders for the year was $3 million, a significant improvement from a loss of $37 million in 2024[18] EBITDA Metrics - Adjusted Core EBITDA for Q4 was $559 million, a 34% increase, and $1,667 million for the full year, up 32% year-over-year[5] - Core EBITDA for the year ended December 31, 2025, was $1,415 million, a 33.2% increase from $1,063 million in 2024[34] - Adjusted Core EBITDA for the year ended December 31, 2025, reached $1,667 million, up from $1,260 million in 2024[34] Operational Expansion - The company opened 95 new operational locations in 2025, ending the year with 385 locations, a 33% increase[5] - The company plans to continue its market expansion and product development initiatives, focusing on enhancing its rental and telematics services to drive future growth[18] Financial Position - The company reported total available liquidity of $1,345 million as of December 31, 2025, including $1,039 million from the asset-based revolving credit facility[14] - Total current assets increased to $1,730 million as of December 31, 2025, from $1,407 million in 2024, driven by higher accounts receivable and inventory levels[20] - Total liabilities rose to $5,099 million as of December 31, 2025, compared to $3,943 million in 2024, primarily due to an increase in long-term debt, which reached $3,268 million[20] Debt and Leverage - Net leverage increased to 3.2x as of December 31, 2025, up from 2.8x in 2024, reflecting the company's capital structure adjustments[14] - Net debt increased to $3,046 million as of December 31, 2025, from $2,235 million in 2024[36] - The net leverage ratio was 3.2x for the year ended December 31, 2025, compared to 2.8x in 2024[36] Equipment and Investment - Original Equipment Cost (OEC) under management increased to $8,780 million, reflecting a $727 million rise in Q4 alone[6] - The company invested $1,780 million in rental equipment during the year ended December 31, 2025, compared to $1,586 million in 2024, reflecting ongoing expansion efforts[22] Segment Performance - Equipment Rental and Services Operations segment revenue increased by 35.4% to $772 million for the three months ended December 31, 2025, compared to $570 million in the same period of 2024[32] - Adjusted EBITDA for the Equipment Rental and Services Operations segment rose by 46.9% to $332 million for the three months ended December 31, 2025, up from $226 million in 2024[32] - The Adjusted EBITDA margin for the Equipment Rental and Services Operations segment improved to 43.0% in Q4 2025, compared to 39.6% in Q4 2024[32] - Equipment Sales segment revenue decreased by 22.4% to $751 million for the three months ended December 31, 2025, down from $968 million in the same period of 2024[32] Future Projections - The company anticipates total revenue for 2026 to be between $5,051 million and $5,471 million, with Rental Segment revenue projected between $3,311 million and $3,587 million[10] - OWN Program payouts are expected to range from $891 million to $947 million in 2026, indicating continued growth in this segment[10]

Production and Sales - The Don David Gold Mine (DDGM) produced and sold a total of 23,125 gold equivalent ounces, consisting of 4,944 gold ounces and 1,461,898 silver ounces, with average prices of $3,657 and $45.48 per ounce respectively[21]. - DDGM produced and sold a total of 23,125 gold equivalent ounces, including 4,944 gold ounces and 1,461,898 silver ounces, with average prices of $3,657 and $45.48 per ounce, respectively[21]. Financial Performance - Total cash costs after co-product credits per gold equivalent ounce sold were $2,205, while all-in sustaining costs per gold equivalent ounce sold were $2,807[21]. - The company ended 2025 with a cash and cash equivalents balance of $25.0 million, an increase of $23.4 million from the previous year, primarily due to improved production and higher metal prices[21]. - Working capital at December 31, 2025, was $32.0 million, reflecting a 1,424% increase from $2.1 million at the end of 2024[21]. - The Company raised $2.5 million through a registered direct offering in January 2025 and $11.4 million in September 2025 from the sale of 25,315,954 shares at $0.45 per share[24]. - The Company raised approximately $8.6 million through its At-The-Market Offering Program during 2025[24]. - The Company received a tax refund of 79.6 million pesos (approximately $4.0 million) related to DDGM taxes paid in 2023[24]. Exploration and Development - The exploration program in 2025 focused on underground grade-control and infill drilling, particularly in the Three Sisters and Arista vein systems, positioning the company for continued expansion drilling in early 2026[21]. - The exploration program in 2025 focused on underground grade-control and infill drilling, with significant advancements in the Three Sisters and Arista vein systems[21]. - The company expects to achieve positive operating income in 2026 based on improvements in production and the development of new areas[23]. - The Company expects 2026 to result in positive operating income based on improved production and new areas being developed[23]. Operational Improvements - The Company engaged a third-party contract miner and upgraded its mining fleet to address equipment availability issues, leading to improved production in the fourth quarter of 2025[22]. - The company received the Mexican Empresa Socialmente Responsable (ESR) award for the eleventh consecutive year in 2025[21].

Financial Performance - TEN Holdings reported total revenues of $3.1 million for fiscal year 2025, a decrease of 11.4% from $3.5 million in fiscal year 2024[8]. - Net loss for the twelve months ended December 31, 2025, was approximately $19.5 million, or $(8.58) per share, compared to a net loss of approximately $3 million, or $(1.78) per share, for the same period in 2024[9]. - Gross profit margin for fiscal year 2025 declined by 2.8% to 78.6% from 81.4% in fiscal year 2024 due to decreased revenues[9]. Customer Acquisition - The number of new customers acquired more than doubled from 6 in the prior year to 16 in fiscal 2025, indicating growing market adoption[6]. Expenses and Cash Flow - Selling, general and administrative expenses increased by approximately $9.9 million, or 183%, to approximately $15.3 million, with $10 million attributed to non-cash related expenses[9]. - Net cash used in operating activities increased to approximately $10.3 million in fiscal year 2025 from $2.5 million in fiscal year 2024, driven by higher operating expenses[12]. - As of December 31, 2025, the Company had total cash of approximately $1.6 million, a significant increase from $48,479 in fiscal year 2024[12]. Strategic Initiatives - The Company plans to enhance its software-as-a-service, Ten Events Pro, to broaden the customer base and generate sustainable recurring revenue streams[12]. - TEN Holdings aims to maximize partnerships with V-Cube and Webinar.net to penetrate new market opportunities[12]. - The Company intends to continue raising capital for investments, partnerships, and acquisitions to enhance competitiveness and growth[12].

Company Overview - The company is a pre-revenue, development-stage biopharmaceutical firm focused on developing new medicines for pain and neuropathy, having acquired Pharmagesic and its subsidiaries[22]. Halneuron® Development - The Halneuron® program is in late-stage clinical development for chemotherapy-induced neuropathic pain (CINP), utilizing highly purified Tetrodotoxin (TTX) as a sodium channel modulator[24]. - The CINP market is estimated at approximately $2.8 billion annually, with a significant opportunity for Halneuron® as the first FDA-approved treatment for CINP[33]. - In a previous Phase 2 study, 51% of patients receiving Halneuron® experienced at least a 30% reduction in pain compared to 35% in the placebo group[34]. - The HAL-CINP-203 Phase 2b clinical trial commenced in Q1 2025, involving approximately 240 patients to assess the efficacy of Halneuron®[41]. - An interim analysis in December 2025 indicated that Halneuron® was separating from placebo, with a sample size of 210-240 expected to provide over 80% power for statistical significance[41]. - The safety profile of Halneuron® is well understood, with common adverse events including numbness and tingling, which are related to sodium channel inhibition[42]. - The company has conducted multiple studies demonstrating that Halneuron® is well tolerated, with no evidence of cumulative toxicity observed over time[45]. - A synthetically formulated version of Halneuron® is under development for Phase 3 and commercialization, with FDA engagement planned for the second half of 2026[81]. - The company plans to advance the Halneuron® Phase 2b clinical trial for the treatment of CINP, with top-line data readout expected in the third quarter of 2026[172]. Other Product Developments - IMC-1 is a combination of famciclovir and celecoxib, with a Phase 3 program including two pivotal trials to demonstrate safety and efficacy in treating fibromyalgia (FM) patients[48]. - The Phase 3 studies will include a four-arm trial comparing IMC-1 to celecoxib, famciclovir, and placebo, and a two-arm study comparing IMC-1 to placebo[48]. - IMC-2, a combination of valacyclovir and celecoxib, is being developed for the treatment of long COVID (LC), with a Phase 2 study planned to assess fatigue improvement as a primary endpoint[50]. - The SP16 program, targeting chemotherapy-induced peripheral neuropathy (CIPN), is in early Phase 1 development, with first in-human studies expected to start in mid-2026[54]. - SP16 has shown preclinical efficacy in alleviating paclitaxel-induced neuropathy and does not interfere with the anticancer activity of taxanes[53]. Intellectual Property and Licensing - The company holds 7 issued families of patents related to Halneuron® as of December 31, 2025, with exclusivity expiring between 2027 and 2030, and pending patents extending exclusivity to 2042 and 2045[59]. - The antiviral portfolio includes 14 issued patents related to IMC-1, with exclusivity extending to 2033[67]. - The company entered into a Know-How License Agreement with the University of Alabama in 2012, granting a 10% membership interest in exchange for a 25-year license to utilize herpesvirus-related technical information[76]. - An Exclusive Licensing Agreement was established with Serpin Pharma and Rejuvenation Labs on September 29, 2025, allowing the company a royalty-free, sublicensable global license for SP16 development[78]. - A Licensing Agreement was established with Serpin, granting a royalty-free global license for the development of SP16, with the issuance of 191,017 shares of common stock and Series A-2 Preferred Stock[152]. Financial Overview - The Company incurred consolidated net losses of $34,257,370 and $12,349,724 for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $108,076,316 as of December 31, 2025[168]. - The Company has not yet generated revenue from the commercialization of any products and anticipates incurring significant additional operating losses for the foreseeable future[169]. - The Company raised approximately $12.5 million in gross proceeds from the January 2026 Offering, with net proceeds of about $11.4 million after deducting fees and expenses[160]. - The company is dependent on obtaining additional capital to fund operations and may face challenges in raising necessary financing[171]. - The company expects its financial condition and operating results to fluctuate significantly from quarter to quarter and year to year[182]. Regulatory Challenges - The company faces significant challenges in obtaining regulatory approval for its product candidates, which is essential for generating sufficient revenue to support future developments[184]. - The regulatory approval process is lengthy and unpredictable, with many factors influencing the timeline, often taking several years after clinical trials commence[196]. - The FDA charges user fees for drug applications, with the NDA application fee exceeding $4.1 million for fiscal year 2025, and an annual program fee of over $400,000 per program[200]. - Compliance with regulatory requirements necessitates substantial investment in manufacturing, quality control, and oversight, which can strain resources[185]. - The company must demonstrate substantial evidence of safety and efficacy through well-controlled clinical trials to gain regulatory approval[199]. - Changes in regulatory policies or requirements could adversely affect the approval process and the company's ability to market its products[188]. - The company may encounter delays in clinical trials due to various factors, including regulatory disagreements and patient recruitment challenges[194]. - Serious adverse events during clinical trials could lead to interruptions or halts, impacting the approval process and commercial viability of products[210]. - The company lacks experience in obtaining regulatory approval in international markets, which could further limit market potential[221]. Market Considerations - The global cancer-related pain market is projected to reach approximately $7.5 billion in annual sales by 2027, with chemotherapy treatment expected to increase by over 50% in the next decade[33]. - The market opportunities for Halneuron® and SP16, if approved, may be smaller than anticipated, with potential target populations being small, which could hinder profitability without additional marketing approvals for other indications[215]. - Even with FDA approval in the United States, the company may face challenges in obtaining approval in other jurisdictions, limiting global market potential[218]. - Coverage and reimbursement from third-party payors are critical for product sales, with significant uncertainty regarding their decisions impacting market access[121][125]. Corporate Structure and Operations - The company has eight full-time employees, with a significant portion of development work outsourced to independent contractors[143]. - The company does not own or lease any location in the U.S. other than a virtual office, while leasing office space for Canadian employees[144]. - The company completed a reverse stock split, converting every 25 shares of common stock into one share, effective October 7, 2024[149]. - The company filed a Form S-3 Registration Statement for the resale of up to 6,433,126 shares of Common Stock, which was declared effective by the SEC on January 29, 2026[161].

Revenue Performance - Total revenue decreased by approximately $0.4 million, or 11.4%, to approximately $3.1 million for the fiscal year ended December 31, 2025, compared to $3.5 million in 2024[173]. - Revenue from virtual and hybrid events was approximately $2.7 million, accounting for 88.2% of total revenue, while physical events revenue increased to approximately $0.4 million, accounting for 11.8%[173]. - Revenue from hybrid, virtual, and physical events is recognized upon completion of the event, reflecting the consideration expected to be received[206]. - Revenue is recognized net of any taxes collected from customers, which are subsequently remitted to government entities[205]. Financial Losses - Net loss for the fiscal year ended December 31, 2025, was approximately $19.5 million, a significant increase from a net loss of approximately $3.0 million in 2024, representing a 557.3% increase[182]. - Selling, general and administrative expenses increased by approximately $9.9 million, or 183%, to approximately $15.3 million, largely due to non-cash expenses related to stock-based compensation[184]. Cash Flow and Liquidity - Operating cash outflows increased from approximately $2.5 million in 2024 to approximately $10.1 million in 2025, driven by higher operating expenses associated with the transition to a public company[194]. - Cash and cash equivalents at the end of the period increased to approximately $1.6 million as of December 31, 2025, compared to $0.05 million in 2024[189]. - The company had access to $18.0 million of liquidity through its ELOC as of December 31, 2025, to support ongoing operations[189]. Capital Expenditures and Obligations - Capital expenditures for the fiscal year ended December 31, 2025, were approximately $0.9 million, a slight decrease from $1.0 million in 2024[199]. - Total contractual obligations for future payments amounted to approximately $6.2 million as of December 31, 2025[197]. Accounting Policies and Estimates - The company applies ASC Topic 606 for revenue recognition, following a five-step model to determine the appropriate revenue amount[203]. - The transaction price for contracts is generally fixed at contract inception, based on agreed rates, and may differ from the final invoice amount[205]. - Management makes estimates regarding credit losses, useful lives of assets, and impairment of long-lived assets, which could differ from actual results[202]. Asset Management - Estimated useful lives for property and equipment include 7 years for computer and equipment, 10 years for furniture and fixtures, and leasehold improvements for the shorter of 10 years or lease term[209]. - Intangible assets consist of capitalized software, which is amortized on a straight-line basis over approximately five to seven years[210]. - Long-lived assets are reviewed for impairment whenever events indicate that carrying amounts may not be recoverable, with impairment losses recognized based on undiscounted cash flows[211]. Subcontractor Engagement - The company engages subcontractors for delivering events and assesses revenue on a gross basis, bearing the risk for services not fully paid by customers[208]. Market Risk Disclosures - The company does not provide quantitative and qualitative disclosures about market risk as it qualifies as a "smaller reporting company"[212].

Company Overview - The company is a pre-revenue, development-stage biopharmaceutical firm focused on developing new medicines for pain and neuropathy, having acquired Pharmagesic and its subsidiaries[22]. Product Development - The lead product candidate, Halneuron®, is in late-stage clinical development for chemotherapy-induced neuropathic pain (CINP), utilizing highly purified Tetrodotoxin (TTX) as its active ingredient[24]. - Halneuron® has shown a potential to reduce pain by modulating the Nav1.7 sodium channel, with a Phase 2 study indicating that 51% of patients experienced at least a 30% reduction in pain compared to 35% in the placebo group[34]. - The HAL-CINP-203 Phase 2b clinical trial commenced in Q1 2025, involving approximately 240 patients, with primary efficacy endpoints focused on pain improvement over 4 weeks[41]. - An interim analysis in December 2025 indicated that Halneuron® was separating from placebo in a subset of 97 patients, suggesting a statistically significant treatment effect[41]. - The overall dropout rate in the study was approximately 4.4%, significantly lower than typical rates for FDA-approved chronic pain medications[41]. Broader Research Strategy - The company is also exploring antiviral therapies for conditions like fibromyalgia and Long-COVID, indicating a broader research strategy beyond pain management[47]. - IMC-1 is a combination of famciclovir and celecoxib, with a Phase 3 program including two pivotal trials to demonstrate safety and efficacy in treating fibromyalgia (FM) patients[48]. - The Phase 3 studies will include a four-arm trial comparing IMC-1 to celecoxib, famciclovir, and placebo, and a two-arm study comparing IMC-1 to placebo[48]. - IMC-2, a combination of valacyclovir and celecoxib, is being developed for the treatment of long COVID (LC), with a Phase 2 study planned to assess fatigue improvement as a primary endpoint[50]. - The Phase 2 study for IMC-2 will be a randomized, double-blind trial lasting 12 weeks[50]. - SP16, a synthetic anti-inflammatory peptide, is in early Phase 1 development and aims to mitigate chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients[54]. - Preclinical studies of SP16 show it alleviates paclitaxel-induced neuropathy and promotes neuronal repair without interfering with chemotherapy efficacy[53]. Intellectual Property - The company holds 7 issued families of patents related to Halneuron® as of December 31, 2025, with exclusivity expiring between 2027 and 2030[59]. - The antiviral portfolio includes 14 issued patents related to IMC-1, with exclusivity extending to 2033[67]. Collaborations and Agreements - The company entered into a Know-How License Agreement with the University of Alabama in 2012, granting a 10% membership interest in exchange for a 25-year license to utilize herpesvirus-related technical information[76]. - An Exclusive Licensing Agreement was established with Serpin Pharma and Rejuvenation Labs on September 29, 2025, allowing the company a royalty-free, sublicensable global license for SP16 development[78]. - The company is collaborating with Serpin Pharma for the supply of SP16 for development research and potential commercialization[82]. Regulatory Environment - The FDA's review process for drug marketing approval typically takes about 10 months from the filing date of a standard NDA[91]. - The FDA may require a REMS plan to ensure that the benefits of a drug outweigh its risks, which can affect market potential and profitability[100]. - The FDA has various expedited review programs, including fast track and priority review, to accelerate the approval process for drugs addressing serious conditions[101][103]. - The FDA may grant accelerated approval to drugs for serious conditions that provide meaningful therapeutic advantages based on surrogate endpoints[108]. - Orphan drug designation can be granted for products intended to treat rare diseases affecting fewer than 200,000 individuals in the U.S.[113]. - Products with orphan status that receive the first FDA approval for their designated condition may obtain seven years of orphan product exclusivity[114]. - The FDA requires post-approval confirmatory studies for drugs granted accelerated approval to verify clinical benefits[112]. - Sales in the U.S. depend significantly on third-party payors' coverage and reimbursement decisions, which can be influenced by the cost-effectiveness of the products[121]. - Third-party payors may challenge pricing and restrict access to branded drugs if cheaper alternatives are available[122]. - The FDA imposes strict regulations on marketing, labeling, and promotion of approved products, with significant penalties for non-compliance[120]. - The Hatch-Waxman Amendments established an abbreviated approval process for generic drugs that are bioequivalent to previously approved drugs[129]. - The FDA may withdraw drug approvals if compliance with regulatory standards is not maintained post-marketing[119]. Financial Overview - The company completed a reverse stock split, converting every 25 shares of common stock into one share, effective October 7, 2024[149]. - In a registered direct offering on March 12, 2025, the company sold 578,950 shares of common stock at $8.26 per share, raising approximately $4.78 million in gross proceeds[151]. - The company raised approximately $12.5 million in gross proceeds from the January 2026 Offering, with net proceeds of approximately $11.4 million after deducting fees and expenses[160]. - As of December 31, 2025, the Company reported consolidated net losses of $34,257,370 and an accumulated deficit of $108,076,316[168]. - The Company has incurred losses since inception and anticipates continuing to incur significant additional operating losses for the foreseeable future[169]. - The Company requires additional capital to fund operations and may face challenges in obtaining necessary financing[171]. - The Company has not yet commercialized any products and has never generated revenue from product commercialization[168]. Clinical Trials and Challenges - The ongoing research and development activities will depend on the successful completion of clinical trials and regulatory approvals[183]. - The Company is heavily dependent on the success of its product candidates, Halneuron® and SP16, which are still under clinical development[183]. - The company faces significant challenges in obtaining regulatory approval for its product candidates, which is essential for generating sufficient revenue and funding future developments[184]. - Clinical trials are expensive and time-consuming, with outcomes that are inherently uncertain, leading to potential delays and failures[193]. - The company may face operational disruptions due to infectious disease outbreaks, impacting supply chains and clinical trial progress[190]. - Regulatory authorities may impose restrictions or require additional studies if safety issues arise, which could adversely affect commercialization efforts[187]. - Changes in regulatory policies could delay or prevent product approvals, impacting the company's ability to achieve profitability[188]. - The company must demonstrate substantial evidence of safety and efficacy through well-controlled clinical trials to gain regulatory approval[199]. - Adverse side effects or serious events during clinical trials could lead to interruptions or delays in the approval process[210]. Market Potential and Risks - The market opportunities for Halneuron® and SP16, if approved, may be smaller than anticipated, with potential target populations being small, which could hinder profitability without additional marketing approvals[215]. - The company has never obtained marketing approval for a product candidate, and there is a risk that the FDA may refuse to accept or approve any NDAs submitted, potentially delaying commercialization[216]. - Any delay in obtaining marketing approvals could prevent the company from commercializing product candidates, generating revenues, and achieving profitability[217]. - Even with FDA approval in the United States, the company may face challenges in obtaining approval in other jurisdictions, limiting global market potential[218]. - Regulatory approval processes vary significantly between jurisdictions, which could lead to increased costs and delays in product introduction[221]. - The company may be required to implement a Risk Evaluation and Mitigation Strategy (REMS) if side effects are identified, which could complicate marketing efforts[219]. - Undesirable side effects identified post-approval could lead to withdrawal of approvals, additional warnings, or restrictions on marketing[213]. - The company may face legal liabilities for harm caused to patients, which could impact its reputation and competitiveness[219]. - Regulatory authorities may impose additional testing requirements for changes to approved products, affecting the company's ability to adapt and innovate[219]. - The company lacks experience in obtaining regulatory approval in international markets, which could further limit market potential[221].

Financial Performance - The company incurred net losses of $140.1 million and $160.9 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $716.3 million as of December 31, 2025[169]. - The company has no products approved for commercial sale and has not generated any product revenue to date, indicating a high degree of uncertainty in evaluating its future success[168]. - The company anticipates significant expenses and operating losses for the foreseeable future, particularly as it progresses its product candidates through preclinical and clinical development[171]. - The company has devoted substantially all financial resources to research and development activities and does not expect to generate revenue from product sales for several years[170]. - The company may require substantial additional capital to finance operations and may be forced to delay or reduce research and drug development programs if unable to raise funds[173][179]. - The company has no current revenue and may need additional funding through equity or debt financing to continue operations[207]. Regulatory Environment - The company is subject to significant regulatory oversight by the FDA and other bodies, which may lengthen the regulatory review process and increase development costs[191]. - The regulatory approval process for the company's novel AAV genetic medicine technology is expected to be more expensive and time-consuming than for other therapeutic modalities, adding to development uncertainty[188]. - The company must comply with regulatory guidelines, and failure to do so may result in delays or discontinuation of product candidate development[194]. - The company has not commenced any regulatory approval applications, which may impede the ability to launch therapies[221]. - Even if regulatory approval is obtained, products will remain subject to ongoing regulatory scrutiny and compliance requirements[271]. - The company may seek accelerated approval for product candidates, but there is no assurance that such applications will be accepted or granted in a timely manner[270]. - Regulatory authorities may impose limitations on approved products, including narrow indications or additional post-marketing studies[268]. - The company anticipates that future healthcare legislation may increase the difficulty and cost of obtaining marketing approvals and affect pricing strategies[295]. Clinical Development - The company initiated Phase 3 studies for wet AMD in 2025, comparing a single dose of 4D-150 at 3E10 vg/eye to on-label aflibercept at 2mg Q8 weeks[209]. - The ability to generate revenue and achieve profitability depends on successful clinical trials, regulatory approvals, and market acceptance of product candidates[204]. - The company may encounter substantial delays in clinical trials due to various factors, including patient enrollment challenges and regulatory requirements[209]. - Limited patient pools for rare genetic diseases may hinder enrollment in clinical trials, affecting statistical significance and regulatory approval[216]. - The need for additional clinical trials may arise if initial trials do not meet statistical significance or safety requirements, delaying regulatory approval[231]. - Clinical trial delays could increase costs and jeopardize the ability to generate revenue, potentially harming the business[213]. Market and Competition - The company faces substantial competition from major pharmaceutical and biotechnology companies, which may hinder its ability to develop and commercialize products successfully[239]. - Competitors include established companies with significant financial resources, making it challenging for the company to gain market acceptance for its product candidates[240]. - The commercial success of genetic medicine product candidates may be adversely affected by public perception regarding safety and ethics, impacting capital raising and strategic agreements[195]. - The company may struggle to establish sales and marketing capabilities, which are crucial for the successful commercialization of approved products[243]. Manufacturing and Supply Chain - Manufacturing gene therapies is complex, and any production problems could delay development or commercialization efforts, impacting the company's business[250]. - The company must comply with cGMP regulations to obtain regulatory approval for its manufacturing processes, and any non-compliance could lead to significant delays[256]. - The company currently relies on third parties for the production of some planned clinical trial drugs and commercial drug materials, which limits control over certain aspects of manufacturing activities[259]. - The company depends on third-party suppliers for key raw materials, and any loss of these suppliers could seriously harm its business[263]. - Any contamination in the manufacturing process or shortages of raw materials could result in delays in research studies and clinical development[261]. Intellectual Property - The company holds five granted patents and two pending patent applications, with some patents being subject to government march-in rights, which could allow the government to license these patents to third parties under certain conditions[336]. - The patent application process is expensive and time-consuming, with no assurance that all necessary patents will be obtained or enforced effectively, which could limit competitive advantages[339]. - The company may face challenges in enforcing patent rights, as detecting infringement can be difficult, and legal proceedings could risk invalidating patents[342]. - The degree of future protection for proprietary rights is uncertain, and there is no guarantee that patents will provide sufficient protection against competitors[344]. - The company may not have control over the prosecution of patents licensed from third parties, which could affect the enforcement of those patents[345]. Compliance and Legal Risks - The company is subject to healthcare regulatory laws that could expose it to penalties, affecting business operations and relationships with stakeholders[318]. - Compliance with healthcare laws may involve substantial costs, and violations could lead to damages, fines, and exclusion from government-funded healthcare programs[321]. - The company relies on third parties for clinical trials and research, which may lead to delays in product development if these parties do not meet their contractual obligations[325]. - The company is responsible for ensuring compliance with Good Clinical Practice (GCP) in clinical trials, and failure to do so could result in fines and adverse publicity[326]. Economic and Legislative Factors - The Inflation Reduction Act of 2022 requires manufacturers to negotiate drug prices with Medicare, with the first negotiated prices effective in 2026 for ten drugs and in 2027 for an additional fifteen drugs[300]. - The One Big Beautiful Bill Act, enacted in July 2025, is expected to significantly reduce Medicaid funding, potentially decreasing enrollment and adversely affecting sales of new product candidates[301]. - Increased scrutiny over drug pricing has led to Congressional inquiries and proposed legislation aimed at enhancing transparency and reducing prescription drug costs, which could impact the pharmaceutical industry[303]. - Individual states are implementing regulations to control pharmaceutical pricing, including price caps and patient reimbursement constraints, which may adversely affect product demand and pricing[304]. - The company anticipates that future healthcare reforms may impose stricter coverage and payment criteria, leading to downward pressure on drug prices and potentially harming revenue generation[306].